Winchester Dialysis is a medicare approved dialysis facility center in Winchester, Virginia and it has 24 dialysis stations. It is located in Winchester City county at 2301 Valor Dr, Winchester, VA, 22601. You can reach out to the office of Winchester Dialysis at (540) 667-0227. This dialysis clinic is managed and/or owned by Davita. Winchester Dialysis has the following ownership type - Profit. It was first certified by medicare in July, 1980. The medicare id for this facility is 492523 and it accepts patients under medicare ESRD program.
| Name | Winchester Dialysis |
|---|---|
| Location | 2301 Valor Dr, Winchester, Virginia |
| No. of Dialysis Stations | 24 |
| Medicare ID | 492523 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 2301 Valor Dr, Winchester, Virginia, 22601 | |
| (540) 667-0227 | |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
| NPI Number | 1063459980 |
| Organization Name | Winchester Dialysis |
| Doing Business As | Total Renal Care Inc |
| Address | 2301 Valor Drive Winchester, Virginia, 22601 |
| Phone Number | (540) 667-0227 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 67% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 16% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 17% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 59% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 26% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 14% |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 69% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 20% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 11% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 70% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 27% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 3% | 12% |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 88% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 12% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 75% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 4% | 12% |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 115 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 15 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 129 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1047 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
| Adult patients getting regular peritoneal dialysis at the center | 52 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 499 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 96 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Winchester Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 202 |
| Hypercalcemia patient months | 1795 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 207 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 16 |
| Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 153 |
| Patient months included in arterial venous fistula and catheter summaries | 1078 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 78 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 178 |
| Hospitalization Rate in facility | 149.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 224.1 |
| Hospitalization Rate: Lower Confidence Limit | 105.6 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at Winchester Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 24.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 31.5 |
| Readmission Rate: Lower Confidence Limit | 18.8 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Winchester Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .24 (Better than Expected) |
| SIR: Upper Confidence Limit | .8 |
| SIR: Lower Confidence Limit | .04 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Winchester Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 161 |
| Transfusion Rate in facility | 9.8 (Better than Expected) |
| Transfusion Rate: Upper Confidence Limit | 28.4 |
| Transfusion Rate: Lower Confidence Limit | 3.8 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at Winchester Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 800 |
| Mortality Rate in facility | 14.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 18.1 |
| Mortality Rate: Lower Confidence Limit | 12 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago
Bio-Medical Applications Of Virginia Inc Location: 38 W. Jubal Early Drive, Winchester, Virginia, 22601 Phone: (540) 535-2254 |
Rutherford Crossing Dialysis Location: 141 Market Street, Winchester, Virginia, 22603 Phone: (540) 665-5169 |
News Archive
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defense against the body's immune system.
MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that the Company has filed its second quarter Form10-Q for the period ended June 30, 2009 with the U.S. Securities and Exchange Commission.
› Verified 1 days ago